C M Bidwell & Associates Ltd. cut its position in Exelixis, Inc. (NASDAQ:EXEL) by 43.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,805 shares of the biotechnology company’s stock after selling 7,670 shares during the period. C M Bidwell & Associates Ltd.’s holdings in Exelixis were worth $298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. North Star Asset Management Inc. bought a new stake in shares of Exelixis in the 4th quarter worth about $1,049,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Exelixis by 29.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,019 shares of the biotechnology company’s stock worth $639,000 after acquiring an additional 4,820 shares during the last quarter. Chicago Equity Partners LLC lifted its holdings in shares of Exelixis by 9.2% in the 4th quarter. Chicago Equity Partners LLC now owns 196,850 shares of the biotechnology company’s stock worth $5,984,000 after acquiring an additional 16,555 shares during the last quarter. Klingenstein Fields & Co. LLC bought a new stake in shares of Exelixis in the 4th quarter worth about $213,000. Finally, IFG Advisory LLC bought a new stake in shares of Exelixis in the 4th quarter worth about $286,000. 80.99% of the stock is owned by hedge funds and other institutional investors.
Shares of Exelixis, Inc. (NASDAQ:EXEL) opened at $28.21 on Friday. The firm has a market cap of $8,350.00, a P/E ratio of 57.57, a price-to-earnings-growth ratio of 0.79 and a beta of 1.84. Exelixis, Inc. has a 12-month low of $18.03 and a 12-month high of $32.50.
In other Exelixis news, Director Alan M. Garber sold 15,000 shares of Exelixis stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total transaction of $454,500.00. Following the completion of the sale, the director now directly owns 64,829 shares in the company, valued at approximately $1,964,318.70. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.
A number of equities research analysts recently weighed in on EXEL shares. SunTrust Banks reiterated a “buy” rating and set a $38.00 price objective on shares of Exelixis in a report on Thursday, December 21st. Needham & Company LLC lifted their price objective on shares of Exelixis from $30.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, October 17th. BidaskClub downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. Cann reissued a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Finally, Oppenheimer reissued a “hold” rating on shares of Exelixis in a research report on Monday, October 16th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Exelixis has a consensus rating of “Buy” and a consensus price target of $32.13.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/11/exelixis-inc-exel-stake-decreased-by-c-m-bidwell-associates-ltd.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.